What question did this study set out to answer?

This study aims to differentiate between side effects and adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis (CF).

February 9, 2026Open Access

“Side versus adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in people with CF”

Key Points

This study aims to differentiate between side effects and adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis (CF).
Analyzed real-world efficacy of elexacaftor/tezacaftor/ivacaftor therapy in adults with CF.
Evaluated the nature and duration of side effects and adverse effects of the therapy.
Side effects from CFTR restoration are mostly self-limiting.
Adverse effects due to drug toxicity are more persistent and often lead to therapy discontinuation.

Abstract

ETI demonstrates robust real-world efficacy in adults with CF. Side effects due to CFTR restoration are generally self-limiting, whereas adverse effects from drug toxicity persist longer and are more frequently cause for permanent discontinuation of ETI.

Bookmark

View Full Paper

Cite This Study

Gorgels et al. (Sun,) studied this question.

synapsesocial.com/papers/698978dff0ec2af6756e71e1 https://doi.org/https://doi.org/10.1016/j.rmed.2026.108697

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper